PURPOSE: Levodopa and dopamine (DA) agonist therapy are two common treatments for Parkinson's disease (PD). There is controversy about the effects of these treatments on disease progression and imaging markers. Here we used multi-tracer positron emission tomography imaging and a unilateral 6-hydroxydopamine (6-OHDA) rat model of PD to evaluate in vivo the effects of chronic levodopa and pramipexole treatments on measurements of vesicular monoamine transporter type 2 (VMAT2), dopamine transporter (DAT) levels, and on levodopa-induced changes in synaptic DA levels [Δ(DA)]. METHODS: Twenty-three unilaterally 6-OHDA lesioned rats underwent an 11C-dihydrotetrabenazine (DTBZ, VMAT2 marker), an 11C-methylphenidate (MP, DAT marker), and a double 11C-raclopride (RAC, D2-type receptor marker) scan. They were assigned to three treatment groups: saline (N=7), pramipexole (N=8), and levodopa (N=8). After 4 weeks of treatment, imaging was repeated. RESULTS: Results showed (1) a significant treatment effect on DTBZ, with pramipexole decreasing DTBZ binding compared to levodopa, (2) significant side and treatment-striatal side interaction effects for MP, indicating that levodopa tends to decrease MP binding compared to pramipexole, and (3) no treatment effect on Δ(DA). CONCLUSION: These data indicate that while chronic dopaminergic pharmacological treatment affects DTBZ and MP binding, it does not affect levodopa-induced changes in synaptic DA level.
PURPOSE:Levodopa and dopamine (DA) agonist therapy are two common treatments for Parkinson's disease (PD). There is controversy about the effects of these treatments on disease progression and imaging markers. Here we used multi-tracer positron emission tomography imaging and a unilateral 6-hydroxydopamine (6-OHDA) rat model of PD to evaluate in vivo the effects of chronic levodopa and pramipexole treatments on measurements of vesicular monoamine transporter type 2 (VMAT2), dopamine transporter (DAT) levels, and on levodopa-induced changes in synaptic DA levels [Δ(DA)]. METHODS: Twenty-three unilaterally 6-OHDA lesioned rats underwent an 11C-dihydrotetrabenazine (DTBZ, VMAT2 marker), an 11C-methylphenidate (MP, DAT marker), and a double 11C-raclopride (RAC, D2-type receptor marker) scan. They were assigned to three treatment groups: saline (N=7), pramipexole (N=8), and levodopa (N=8). After 4 weeks of treatment, imaging was repeated. RESULTS: Results showed (1) a significant treatment effect on DTBZ, with pramipexole decreasing DTBZ binding compared to levodopa, (2) significant side and treatment-striatal side interaction effects for MP, indicating that levodopa tends to decrease MP binding compared to pramipexole, and (3) no treatment effect on Δ(DA). CONCLUSION: These data indicate that while chronic dopaminergic pharmacological treatment affects DTBZ and MP binding, it does not affect levodopa-induced changes in synaptic DA level.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: M G Murer; G Dziewczapolski; L B Menalled; M C García; Y Agid; O Gershanik; R Raisman-Vozari Journal: Ann Neurol Date: 1998-05 Impact factor: 10.422
Authors: Vesna Sossi; James E Holden; Geoffrey J Topping; Marie-Laure Camborde; Rich A Kornelsen; Siobhan E McCormick; Jennifer Greene; Andrei R Studenov; Thomas J Ruth; Doris J Doudet Journal: J Cereb Blood Flow Metab Date: 2007-01-24 Impact factor: 6.200
Authors: R de la Fuente-Fernández; J Q Lu; V Sossi; S Jivan; M Schulzer; J E Holden; C S Lee; T J Ruth; D B Calne; A J Stoessl Journal: Ann Neurol Date: 2001-03 Impact factor: 10.422
Authors: P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross Journal: CNS Neurol Disord Drug Targets Date: 2006-02 Impact factor: 4.388
Authors: Vesna Sossi; Katherine Dinelle; Geoffrey J Topping; James E Holden; Doris Doudet; Michael Schulzer; Thomas J Ruth; A Jon Stoessl; Raul de la Fuente-Fernandez Journal: J Neurochem Date: 2009-01-22 Impact factor: 5.372
Authors: Manuel Rodriguez; Sergio Gonzalez; Ingrid Morales; Magdalena Sabate; Tomas Gonzalez-Hernandez; Jose Luis Gonzalez-Mora Journal: Eur J Neurosci Date: 2007-05 Impact factor: 3.386
Authors: Connor Wj Bevington; Ju-Chieh Kevin Cheng; Ivan S Klyuzhin; Mariya V Cherkasova; Catharine A Winstanley; Vesna Sossi Journal: J Cereb Blood Flow Metab Date: 2020-02-12 Impact factor: 6.200
Authors: Susanne Nikolaus; Markus Beu; Angelica Maria De Souza Silva; Joseph P Huston; Hubertus Hautzel; Owen Y Chao; Christina Antke; Hans-Wilhelm Müller Journal: Front Behav Neurosci Date: 2014-12-17 Impact factor: 3.558
Authors: Jae Woo Chung; Roxana G Burciu; Edward Ofori; Priyank Shukla; Michael S Okun; Christopher W Hess; David E Vaillancourt Journal: Neuroimage Clin Date: 2017-02-16 Impact factor: 4.881
Authors: Jae Woo Chung; Roxana G Burciu; Edward Ofori; Stephen A Coombes; Evangelos A Christou; Michael S Okun; Christopher W Hess; David E Vaillancourt Journal: Neuroimage Clin Date: 2018-05-18 Impact factor: 4.881
Authors: Susanne Nikolaus; Markus Beu; Hubertus Hautzel; Angelica M De Souza Silva; Christina Antke; Andreas Wirrwar; Joseph P Huston; Hans-Wilhelm Müller Journal: Nucl Med Commun Date: 2013-12 Impact factor: 1.690
Authors: Florian Krismer; Kurt A Jellinger; Sonja W Scholz; Klaus Seppi; Nadia Stefanova; Angelo Antonini; Werner Poewe; Gregor K Wenning Journal: Parkinsonism Relat Disord Date: 2014-05-21 Impact factor: 4.891
Authors: Maria A de Souza Silva; Claudia Mattern; Cvetana Decheva; Joseph P Huston; Adolfo G Sadile; Markus Beu; H-W Müller; Susanne Nikolaus Journal: Front Behav Neurosci Date: 2016-04-22 Impact factor: 3.558
Authors: Marco Onofrj; Angelo Di Iorio; Claudia Carrarini; Mirella Russo; Raffaella Franciotti; Alberto J Espay; Laura S Boylan; John-Paul Taylor; Massimo Di Giannantonio; Giovanni Martinotti; Enza M Valente; Astrid Thomas; Laura Bonanni; Stefano Delli Pizzi; Fedele Dono; StefanoL Sensi Journal: Mov Disord Date: 2021-08-24 Impact factor: 9.698